Skip to main content
Log in

Immunotherapie voor inhalatieallergenen op de kinderleeftijd

Herziene consensus sectie kinderallergologie van de NVK

  • artikelen
  • Published:
Tijdschrift voor Kindergeneeskunde

Samenvatting

De behandeling van allergische rhinoconjunctivitis bestaat primair uit vermijding van het allergeen en symptomatische therapie. Als er ondanks maximale medicamenteuze therapie klachten blijven bestaan of indien medicamenteuze therapie niet mogelijk of gewenst is, kan immunotherapie overwogen worden. Specifieke immunotherapie met allergeenextracten heeft tot doel een allergische patiënt minder gevoelig te maken voor een specifiek allergeen (hyposensibilisatie). Voor kinderen met een therapieresistente inhalatieallergie is subcutane immunotherapie een effectieve behandeling die – mits protocollair uitgevoerd – veilig is. Als alternatief voor het maandelijks prikken zijn er inmiddels ook effectieve sublinguale toedieningsvormen ontwikkeld in de vorm van een smelttablet. Vooralsnog is deze toedieningsvorm echter alleen beschikbaar voor graspollenallergie.

Summary

Therapy for allergic rhino conjunctivitis exists of avoiding of contact with allergens and symptomatic therapy. For structural treatment immunotherapy can be considered. Immunotherapy with allergen extracts can be used to treat allergies by desensitisation. When performed by protocol subcutaneous immunotherapy is effective and safe in children with a therapy resistant inhalation allergy. As an alternative for the monthly injections sublingual tablets for sublingual immunotherapy have recently been proven to be effective. However, until now these tablets are only available for grass pollen allergy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatuur

  1. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341:468–75

    Article  PubMed  CAS  Google Scholar 

  2. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129:717–25

    Article  PubMed  Google Scholar 

  3. Röder E, Berger MY, Groot H de, Wijk RG van. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol. 2008;19:197–207

    Article  PubMed  Google Scholar 

  4. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943– 8.

    Article  PubMed  CAS  Google Scholar 

  5. Jacobsen L,Wahn U, Bilo MB. Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit – the centenary of allergen specific subcutaneous immunotherapy. Clin Transl Allergy. 2012;2:8.

    Article  PubMed  CAS  Google Scholar 

  6. Larenas-Linnemann DE, Pietropaolo-Cienfuegos DR, Calderón MA. Evidence of effect of subcutaneous immunotherapy in children: complete and updated review from 2006 onward. Ann Allergy Asthma Immunol. 2011;107:407–16

    Article  PubMed  Google Scholar 

  7. Bousquet J, Lockey RF, Malling HJ.WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998;53(suppl 44):1–42

    Google Scholar 

  8. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin Immunol. 2001;108:S147–334

    Article  PubMed  CAS  Google Scholar 

  9. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009;123:167–73

    Article  PubMed  CAS  Google Scholar 

  10. Bufe A, Roberts G. Specific immunotherapy in children. Clin Exp Allergy. 2011;41:1256–62

    Article  PubMed  CAS  Google Scholar 

  11. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123:160–6

    Article  PubMed  CAS  Google Scholar 

  12. Groot H de, Bijl AMH. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy. 2009;64:963–4

    Article  PubMed  Google Scholar 

  13. Groot H de, Leer EHG van, Duijvestijn YCM. Immunotherapie op de kinderleeftijd. Tijdschr Kindergeneeskd. 2008;76:78–83

    Article  Google Scholar 

  14. Eng PA, Borer-Reinhold M, Heijnen IAFM, Gnehm HPE. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy. 2006;61:198–201

    Article  PubMed  CAS  Google Scholar 

  15. Valovirta E, Berstad AK, de Blic J, et al. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Clin Ther. 2011;33: 1537–46

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

kinderarts

kinderarts-allergoloog

allergoloog

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duijvestijn, Y.C.M., van Leer, E.H.G. & de Groot, H. Immunotherapie voor inhalatieallergenen op de kinderleeftijd. TIJDSCHR. KINDERGENEESKUNDE 80, 108–111 (2012). https://doi.org/10.1007/s12456-012-0031-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12456-012-0031-5

Navigation